Lupin Limited (LUPIN) — Announcement Announcement
📢 Key Event
Lupin partners with ERN to launch Luforbec® inhaler in Spain
💡 Investor Takeaway
This partnership expands Lupin's European respiratory footprint and could drive future revenue growth from new markets.
Lupin announced a strategic partnership with Spanish pharmaceutical company ERN to launch Luforbec® (beclometasone/formoterol) pMDI for asthma and COPD in Spain, leveraging Lupin's respiratory expertise and ERN's market reach to expand access to quality inhalers across the country.
📄 View Original Announcement (PDF)
About Lupin Limited (LUPIN)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,04,071.47 Cr
P/E: 36.2
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.